ArticleJournal of cardiothoracic surgery2026
A new insight of hypertrophic cardiomyopathy: integrated analysis of differentially expressed genes, expression quantitative trait loci, and mendelian randomization.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertrophic cardiomyopathy (HCM) has a genetic basis, with pathogenic variants identified in the majority of familial cases and unclear mechanism. This study aimed to identify the genetic contributors underlying HCM pathogenesis and to identify novel genetic targets of HCM via integrated analysis of microarray datasets.
methodsThree independent HCM datasets were used for comprehensive analysis by using R software. Differentially expressed genes (DEGs) between HCM and control, expression quantitative trait loci (eQTL) analysis, and Two-Sample Mendelian Randomization (TSMR) analyses were performed to identify the novel genes. CIBERSORT was utilized for immune cell infiltration analysis. Finally, the identified genes were verified, and their targeted drugs were explored.
resultsTSMR analysis revealed that four significantly HCM co-expressed genes, TNNT1, KCNK17, GADD45B, and CXCL6, were enriched in essential biological processes and pathways, including macrophage activation and neural system regulation. TNNT1 and CXCL6 genes were validated as the novel genes, enhancing the reliability of our findings. The candidate compounds with predicted binding affinity (Atorvastatin, Zearalenone, Cotinine, and S-1,2-Dichlorovinyl-N-acetylcysteine) were predicted and molecular docking was performed to evaluate the binding ability of the drug to the protein.
conclusionsThis study reveals a new molecular insight in the pathogenesis of HCM, highlighting TNNT1 and CXCL6 as candidate targets in specific molecular pathways for the interference of HCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.